Previous close | 2.5000 |
Open | 2.4600 |
Bid | 2.3000 x 200 |
Ask | 2.3100 x 600 |
Day's range | 2.3000 - 2.4600 |
52-week range | 0.5000 - 3.2200 |
Volume | |
Avg. volume | 2,240,548 |
Market cap | 345.757M |
Beta (5Y monthly) | 1.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8000 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.75 |
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With the business potentially at an important milestone, we thought we'd take a closer look at Heron Therapeutics...
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.